Abstract: Disclosed herein are methods and compositions for alleviating side effects of statin administration, such as myopathic or myalgic side effects, short-term memory loss, abnormal liver function, glucose intolerance, hyperglycemia, increased risk for diabetes, or cumulative trauma disorder, comprising administration of ?-hydroxy ?-methylbutyrate (HMB) to an individual taking a statin. Also disclosed are methods and compositions for alleviating acute rhabdomyolysis comprising administration of HMB. The disclosure further provides uses of HMB in combination with a statin to alleviate side effects of statin administration.
Abstract: The present invention includes cilastatin or a pharmaceutically acceptable salt thereof as an active component and a suppressant for renal impairment or inner ear disorders, induced via megalin by at least one megalin ligand which is selected from the group consisting of polymyxins, aminoglycoside antibiotics, glycopeptide antibiotics, cisplatin, and pharmaceutically acceptable salts thereof
Type:
Application
Filed:
July 21, 2016
Publication date:
November 10, 2016
Applicants:
EA Pharma Co., Ltd., Niigata University
Abstract: Compositions including an odd chain fatty acid, and salts and derivatives thereof, and methods for metabolic syndrome treatment and prophylaxis are provided, including compositions and methods for treating diabetes, obesity, hyperferritinemia, elevated insulin, glucose intolerance, dyslipidemia and related conditions. Methods for the diagnosis and monitoring of metabolic syndrome are also provided.
Abstract: The present invention provides a prophylactic and/or therapeutic drug for diabetes, which contains 8-[2-(2-pentyl-cyclopropylmethyl)-cyclopropyl]-octanoic acid (DCP-LA) as an active ingredient, particularly a prophylactic and/or therapeutic drug for diabetes, which promotes sugar intake into the cells, and the like.
Type:
Application
Filed:
January 6, 2015
Publication date:
November 10, 2016
Applicant:
NISHIZAKI BIOINFORMATION RESEARCH INSTITUTE
Abstract: The present invention is directed toward fatty acid-based particles, and methods of making such particles. The particles can be associated with an additional, therapeutic agent. Also provided herein is a method of forming fatty acid particles, comprising associating a cross-linked, fatty acid-derived biomaterial with a cryogenic liquid; and fragmenting the bio material/cryogenic liquid composition, such that fatty acid particles are formed. The particles can be used for a variety of therapeutic applications.
Type:
Application
Filed:
July 22, 2016
Publication date:
November 10, 2016
Applicant:
ATRIUM MEDICAL CORPORATION
Inventors:
Thomas M. SWANICK, Joseph FERRARO, Lisa ROGERS, Paul MARTAKOS
Abstract: The present invention is directed to compositions comprising physiologically acceptable, metabolic lipids, and physiologically acceptable, preferably biodegradable controlled release (CR) compounds, wherein the lipids are cell-free and the CR compounds release the metabolic lipids over a delayed time period under physiological conditions. In addition, the present invention relates to the use of such a composition for producing a cosmetic or therapeutic composition, preferably for fat tissue expansion or fat tissue repair. Also, the invention pertains to a method for the therapeutic or cosmetic treatment of a mammal comprising the administration of the composition of the invention and preferably injecting the composition while withdrawing the injection needle until the tissue area of interest is treated.
Abstract: Ready-to-use diet food composition to reduce low-grade inflammation and stabilize weight loss in the long term in an obese or overweight patient comprising, as a proportion of the total weight of the composition: 50% to 80% by weight of protein; 2% to 20% by weight of carbohydrates; and, 2% to 15% by weight of lipids; said lipids including 0.25% to 2% by weight of docosahexaenoic acid (DHA) relative to said weight of lipids. The invention also concerns ready-to-use portions of diet food, a kit comprising a food portion and DHA capsules as well as the use of DHA to prepare a food composition or food portions according to the invention.
Abstract: The present invention provides a compound which is a polyunsaturated fatty acid (PUFA) derivative of formula (I), or a pharmaceutically acceptable salt, or solvate thereof, for use in treating various skin disorders.
Type:
Application
Filed:
July 18, 2016
Publication date:
November 10, 2016
Inventors:
Adam Kelliher, Angus Morrison, Phil Knowles
Abstract: The disclosure provides compositions comprising 15-HEPE or derivatives thereof used singly or in combination with other active agents for the treatment and/or prevention of lung diseases and disorders such as asthma.
Abstract: A method for treatment of a cardiovascular or renal condition or disease with a specific combination, linked pro-drug or a compound of an angiotensin receptor antagonist and a NEPi.
Type:
Application
Filed:
June 21, 2016
Publication date:
November 10, 2016
Inventors:
Lili Feng, Sven Erik Godtfredsen, Paul Allen Sutton, Mahavir Prashad, Michael J. Girgis, Bin Hu, Yugang Liu, Thomas J. Blacklock, Piotr Henryk Karpinski
Abstract: The present invention relates to a dosage regimen of ST10 (ferric trimaltol) for the treatment of patients suffering from iron deficiency with or without anaemia. Specifically the invention relates to the treatment of patients with 30 mg ST10 twice daily.
Type:
Application
Filed:
January 6, 2015
Publication date:
November 10, 2016
Inventors:
Christian Schweiger, Carl Andrew Sterritt, Julian David Howell
Abstract: The invention relates the method of treatment or amelioration of mitochondrial disorders such as Alzheimer's disease, Parkinson's disease, Friedreich's ataxia (FRDA), cerebellar ataxias, Leber's hereditary optic neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Myoclonic Epilepsy with Ragged Red Fibers (MERFF), amyotrophic lateral sclerosis (ALS), motor neuron diseases, Huntington's disease, macular degeneration, and epilepsy, with chroman derivatives of Formula I or Formula II as described herein.
Type:
Application
Filed:
June 22, 2016
Publication date:
November 10, 2016
Inventors:
Gail WALKINSHAW, Sekhar BODDUPALLI, Bing WANG, Guy M. MILLER
Abstract: The present invention relates to a cosmetic composition containing a hydroxypyranone derivative compound as an active ingredient for promoting the differentiation of adipocytes. The composition according to the present invention has an effect of promoting the differentiation of adipocytes, and thus allows the differentiation of adipocyte in a skin layer, thereby increasing the skin volume or elasticity. Therefore, the composition of the present invention can be variously used as a cosmetic composition or a pharmaceutical composition in the field, such as skin damage.
Type:
Application
Filed:
January 20, 2015
Publication date:
November 10, 2016
Inventors:
Ho Sik RHO, Heung Soo BAEK, Yu Jung KIM, Song Seok SHIN, John Hwan LEE
Abstract: A medicament for inhibiting platelet aggregation, comprising atractylenolide compound or its derivatives, wherein the said atractylenolide compound has the following structural formula shown in formula (I), wherein R1 represents H or C1-C10 linear or branched alkyl, R2 represents H or C1-C10 linear or branched alkyl, and R3 represents H or hydroxyl. Use of atractylenolide compound shown in formula (I) or its derivatives in the manufacture of a medicament for inhibiting platelet aggregation. The medicament for inhibiting platelet aggregation of the present application has good efficacy without toxic-and-side effect, lower tendency of tolerance, convenient to take and applicable for preventing or treating diseases caused by high platelet aggregation rate.
Abstract: A method for providing an increased expression of at least one of telomerase, brain-derived neurotrophic factor (BDNF), stromal cell-derived factor-1 (SDF1), CXC chemokine receptor 4 (CXCR4), and an immune regulatory factor of a stem cell in a subject is provided. The method comprises simultaneously or separately administering to the subject an effective amount of (a) a phthalide and (b) a stem cell.
Abstract: Provided herein is a zileuton cream type topical anti-inflammatory pharmaceutical composition, and more particularly, a zileuton cream type topical anti-inflammatory pharmaceutical composition capable of retaining stability at room temperature and of being applied topically to maximize medical effects while minimizing absorption to an entirety of body, thereby minimizing toxicity caused by the compound so as to be suitable to topical treatment of skin diseases caused by leukotriene.
Type:
Application
Filed:
July 21, 2016
Publication date:
November 10, 2016
Inventors:
Ki Yean NAM, Jeong Jun KIM, Soo Hyun OH, Sae Yeon LEE, Ji Ye AHN
Abstract: This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterized by cytotoxic ?-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.
Abstract: The present invention describes benzimidazole derivatives of Formula (I) which constitute potent PARP inhibitors in combination with temozolomide (TMZ).
Abstract: The invention provides methods for treating multiple sclerosis by administering biotin. The invention also provides methods for treating sequelae after multiple sclerosis attacks by administering biotin.
Abstract: The present invention relates to a pharmaceutical composition comprising deferasirox, a process for preparing such pharmaceutical composition, and its use in the treatment of chronic iron overload. The pharmaceutical composition comprises nanosized deferasirox having improved surface area and solubility. It also relates to a method for treatment of chronic iron overload which comprises administering a pharmaceutical composition comprising nanosized deferasirox.
Abstract: Use of alkylamidothiazoles in cosmetic or dermatological preparations for the prophylaxis and treatment of sensitive skin, itching, dry skin, and of inflammatory states of the human skin.
Type:
Application
Filed:
November 21, 2014
Publication date:
November 10, 2016
Applicant:
BEIERSDORF AG
Inventors:
Ludger KOLBE, Cathrin SCHERNER, Ursula WENNSORRA, Tobias MANN
Abstract: Novel spirocyclic compounds of formula I: and pharmaceutically acceptable salts thereof are disclosed as inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. Pharmaceutical compositions and methods of treatment are also included.
Type:
Application
Filed:
December 19, 2014
Publication date:
November 10, 2016
Inventors:
Shuzhi Dong, Alexander Pasternak, Xin Gu, Qinghong Fu, Jinlong Jiang, Fa-Xiang Ding, Haifeng Tang, Reynalda K. DeJesus, Takao Suzuki
Abstract: It is disclosed herein that treatment of a subject with an mTOR inhibitor enhances antigen-specific T cell immune responses. Thus, provided herein is a method of enhancing an antigen-specific T cell response in a subject by administering to the subject a therapeutically effective amount of an mTOR inhibitor. The antigen can be any antigen, such as an antigen from a pathogen or a vaccine, or a tumor antigen. In some embodiments, the method further comprises administering to the subject a vaccine, such as a virus vaccine or a cancer vaccine. The mTOR inhibitor can be administered either before or after vaccination to enhance the quantity and quality of the T cell immune response and immunological memory. In some examples, the mTOR inhibitor is rapamycin or a rapamycin analog.
Type:
Application
Filed:
May 16, 2016
Publication date:
November 10, 2016
Inventors:
Rafi R. Ahmed, Christian P. Larsen, Koichi Araki
Abstract: Disclosed are compositions and methods related to the use of kinase inhibitors in treating macular degeneration and/or retinal vein occlusion.
Abstract: The present invention provides a physically and chemically stable pharmaceutical liquid composition including sodium picosulfate, magnesium oxide, citric acid and malic acid and methods of making and using such a composition.
Abstract: Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino) acetate, or a salt thereof. The pharmaceutical preparation has an excellent intraocular pressure lowering effect and may be used as a therapeutic or preventive agent for glaucoma or ocular hypertension or an intraocular pressure lowering agent.
Abstract: The present invention provides dosing regimens for administering pharmacological chaperones to a subject in need thereof. The dosing regimens can be used to treat disorders caused by improper protein misfolding, such as lysosomal storage disorders.
Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
Type:
Application
Filed:
July 15, 2016
Publication date:
November 10, 2016
Inventors:
Sean Cunningham, Seamus Mulligan, Michael Myers
Abstract: The present invention generally relates to the early prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children. For example, the present invention relates to the prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in infants or children through appropriate nutrition for women desiring to get pregnant and/or during pregnancy and/or lactation. Embodiments of the present invention relate to the Vitamin B6 for use in the prevention of overweight, obesity, excessive fat accumulation and/or associated metabolic disorders in the offspring, wherein the vitamin B6 is administered to women desiring to get pregnant and/or to the mother during pregnancy and/or lactation and to maternal food compositions that can be used for this purpose.
Type:
Application
Filed:
January 9, 2015
Publication date:
November 10, 2016
Inventors:
Cyrus Cooper, Peter David Gluckman, Keith Malcolm Godfrey, Catherine Nace, Irma Siliva Zolezzi
Abstract: The invention relates to methods for decreasing adverse events associated with pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy. The invention discloses an optimized dose escalation scheme that results in the patient having increased tolerance to adverse events associated with the administration of pirfenidone. The invention also discloses a starter pack that may be used in conjunction with the dose escalation scheme.
Abstract: The present invention relates to an anticancer supplement containing loperamide as an active ingredient. More specifically, a proteasome inhibitor alone cannot exhibit an anticancer effect on solid cancers and some blood cancers, but when the proteasome inhibitor and loperamide are co-administered or a composition containing the proteasome inhibitor and loperamide is provided, cancer cell death by the proteasome inhibitor can be effectively induced, thereby exhibiting an improved anticancer effect, and enhancing anticancer effects on solid cancers and blood cancers while reducing side effects caused by a high-concentration of the proteasome inhibitor. Therefore, the composition containing the proteasome inhibitor and loperamide as active ingredients, according to the present invention, can be useful for preventing or treating cancer, and loperamide can be provided as an anticancer supplement when the proteasome inhibitor is used to treat cancer.
Type:
Application
Filed:
September 17, 2014
Publication date:
November 10, 2016
Applicant:
AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUN DATION
Inventors:
Kyeong Sook CHOI, In Young KIM, Mi Jin YOON, A Reum LEE
Abstract: Methods for reducing the glycation of nutrient and endogenous proteins and methods for reducing the peroxidation of nutrient and endogenous lipids are provided herein. Several inhibitors and conditions of inhibiting glycation of nutrient and endogenous proteins and peroxidation of nutrient and endogenous lipids are also provided herein. Also provided are the methods for inhibiting and treating the conditions associated with the formation of glycated proteins, such as Alzheimer's disease, neuropathy, retinopathy and nephropathy and the methods for inhibiting and treating the conditions associated with the formation of peroxidized lipids, such as cancer and atherosclerosis.
Abstract: The present disclosure relates generally to the field of nicotine delivery. The disclosure teaches a nicotine meta-salicylate. More specifically, the disclosure teaches a condensation nicotine aerosol where nicotine meta-salicylate is vaporized. This disclosure relates to aerosol nicotine delivery devices. The delivery devices can be activated by actuation mechanisms to vaporize thin films comprising a nicotine meta-salicylate. More particularly, this disclosure relates to thin films of nicotine salt with meta salicylic acid for the treatment of nicotine craving and for effecting smoking cessation.
Abstract: Pharmaceutical compositions comprising 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1) in Form I and a solid dispersion comprising substantially amorphous N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (Compound 2), methods of treating, lessening the severity of, or symptomatically treating CFTR mediated diseases, such as cystic fibrosis, methods of manufacturing, methods of administering, and kits thereof are disclosed.
Type:
Application
Filed:
May 11, 2016
Publication date:
November 10, 2016
Applicant:
Vertex Pharmaceuticals Incorporated
Inventors:
Marinus Jacobus Verwijs, Radhika Karkare, Michael Douglas Moore
Abstract: The present invention aims to prevent and/or treat malaria using an antimalarial drug comprising, as an active ingredient, a metal chelator represented by the following formula (I), (III), (IV), (V), (VI), or (VII), such as tris(2-pyridylmethyl)amine.
Abstract: This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics.
Abstract: The present invention provides abuse deterrent mucoadhesive devices for delivery of buprenorphine. Each device comprises a mucoadhesive layer and a backing layer, and the pH in each layer is selected, such that absorption of buprenorphine is maximized.
Type:
Application
Filed:
July 18, 2016
Publication date:
November 10, 2016
Applicant:
BioDelivery Sciences International, Inc.
Abstract: Model systems have shown that shifting a cell's reliance from oxidative phosphorylation (OXPHOS) to glycolysis can protect against cell death. Exploiting the therapeutic potential of this strategy, however, has been limited by the lack of clinically safe agents that remodel energy metabolism. The present invention identifies non-toxic small molecules (e.g., drug-like compounds) that are capable of modulating oxidative metabolism. One identified compound comprises meclizine. As described herein, meclizine, and its enantiomer S-meclizine, redirects OXPHOS to glycolysis. Such compounds could be protective or therapeutic in degenerative disorders such as diabetes, Huntington's, Parkinson's, and Alzheimer's disease and/or ischemic disorders including, but not limited to, stroke, heart attack, or reperfusion injuries.
Type:
Application
Filed:
July 22, 2016
Publication date:
November 10, 2016
Inventors:
Vamsi K. Mootha, Vishal Gohil, Sunil Sheth, Yuhua Ji
Abstract: The present application relates to new uses of 5-HT6 receptor antagonists, specifically high doses of 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline, and to the combination of 5-HT6 receptor antagonists, specifically 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline, with, an acetylcholinesterase inhibitor for the treatment of a neurodegenerative disease.
Type:
Application
Filed:
May 6, 2016
Publication date:
November 10, 2016
Inventors:
Lawrence Tim FRIEDHOFF, Stephen Clement PISCITELLI, Kunal KISHNANI, Shankar RAMASWAMY, Bryan M. LEWIS
Abstract: The present application relates to new uses of 5-HT6 receptor antagonists, specifically 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline or pharmaceutically acceptable salts, hydrates, solvates, or polymorphs, thereof, and to the combination of 5-HT6 receptor antagonists, specifically 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline or pharmaceutically acceptable salts, hydrates, solvates, or polymorphs, thereof, with other therapeutic agents for the treatment of a neurodegenerative disease.
Type:
Application
Filed:
May 6, 2016
Publication date:
November 10, 2016
Inventors:
Lawrence Tim FRIEDHOFF, Melissa RHODES, Stephen Clement PISCITELLI, Kunal KISHNANI, Shankar RAMASWAMY, Bryan M. LEWIS, Geetha RAMASWAMY
Abstract: A process of production of trazodone or trazodone hydrochloride that comprises: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature of at least 40° C. for at least 30 minutes; (e) recovering said trazodone; and optionally, (f) treating said trazodone with hydrochloric acid to obtain trazodone hydrochloride. Trazodone or trazodone hydrochloride comprising less than 15 ppm of alkylating substances, and a pharmaceutical composition comprising said trazodone hydrochloride.
Type:
Application
Filed:
July 18, 2016
Publication date:
November 10, 2016
Applicant:
AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R. A.F. S.p.A.
Inventors:
Marcello MARCHETTI, Tommaso IACOANGELI, Giovanni Battista CIOTTOLI, Giuseppe BIONDI
Abstract: The present invention relates to pharmaceutical compositions suitable for oral administration, and more particularly to pharmaceutical compositions, including pharmaceutical tablet compositions, containing N-(2-{2-dimethylaminoethyl-methyl-amino}-4-methoxy-5-[4-(1-methylindol-3-yppyrimidin-2-yl]amino phenyl)prop-2-enamide (“AZD9291”) or a pharmaceutically Cacceptable salt thereof, wherein such compositions comprise a certain amount of microcrystalline cellulose and at least one other pharmaceutical diluent.
Type:
Application
Filed:
January 2, 2015
Publication date:
November 10, 2016
Applicant:
AstraZeneca AB
Inventors:
Cindy FINNIE, Steven Anthony RAW, David WILSON
Abstract: A pharmaceutical composition of 3-(1-{3-[5-(1-Methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile or a pharmaceutically acceptable salt and/or solvate thereof in combination with Gefitinib.
Abstract: The present disclosure relates to methods, uses, pharmaceutical compositions and kits comprising a sGC stimulator or a pharmaceutically acceptable salt thereof, alone or in combination with one or more additional therapeutic agents, for the treatment of a neuromuscular disorder associated with loss or alteration of function of nitric oxide synthase (NOS).
Type:
Application
Filed:
January 13, 2015
Publication date:
November 10, 2016
Inventors:
Kimberly Kafadar LONG, George Todd MILNE, Mark G. CURRIE
Abstract: The present application discloses a method of treating a Varicella-Zoster Virus (VZV) infection in an individual in need thereof, including the step of administering to said individual an effective Varicella-Zoster Virus antiviral amount of a compound called N-methanocarbathymidine (N-MCT), which has a northern configuration with the structure as follows
Type:
Application
Filed:
May 3, 2016
Publication date:
November 10, 2016
Inventors:
Jennifer MOFFAT, DONGMEI LIU, WANDA COOMBS, MICHAEL APPEL, AQUILUR RAHMAN
Abstract: This invention generally relates to compositions and methods for cancer treatment and, in particular, to compositions able to interact (e.g., bind to) with MUC1 growth factor receptor or its ligands, and methods for treating the same. The invention also relates to assays or use of such compositions for the treatment of patients susceptible to or exhibiting symptoms characteristic of cancer or tumorigenesis. Other compositions of the present invention useful for the treatment or prevention of cancer or tumorigenesis include homologs, analogs, derivatives, enantiomers or functional equivalents. The present compositions can also be packaged in kits in some cases.
Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
Type:
Application
Filed:
March 10, 2016
Publication date:
November 10, 2016
Inventors:
Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody